Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children’s Hospital of Philadelphia

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that it has strengthened its discovery and research platform by extending its genomics collaboration with the Center for Applied Genomics (CAG) at Children’s Hospital of Philadelphia (CHOP). The amendment to the existing agreement with CHOP grants the Company options for long-term exclusive access to certain data and samples from the CAG biobank and certain discoveries in rare and orphan diseases. Aevi Genomics has also renewed its Sponsored Research Agreement (SRA) with CHOP. The extension of the SRA marks the third renewal of sponsored research at CHOP, jointly focused on the genetics of rare and orphan pediatric disease.

This entry was posted in Recent Development News: Q1 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »